According to a recent LinkedIn post from HistoSonics, the company is highlighting the first patient treatments in WOLVERINE, a prospective feasibility trial of its Edison histotripsy system for benign prostatic hyperplasia at Prince of Wales Hospital in Hong Kong. The post notes that BPH affects a large global male population and emphasizes the non-invasive nature of histotripsy compared with traditional, more invasive treatment options.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post further suggests that this milestone is viewed internally as progress toward expanding histotripsy’s use across a broader range of serious clinical conditions. For investors, early feasibility activity in BPH could indicate a strategic push into a large urology market, but clinical, regulatory, and reimbursement outcomes remain key determinants of any future revenue impact.
Locating the trial at a major teaching hospital affiliated with The Chinese University of Hong Kong may also signal an effort to build clinical evidence and regional reference sites in Asia. If subsequent data are positive and the technology differentiates itself on safety, recovery time, or procedural efficiency, HistoSonics could strengthen its positioning within the medtech sector, though commercialization timelines and capital needs are not addressed in the post.